Wang C, Li J, Xue H et al (2015) Type 2 diabetes mellitus incidence in Chinese: contributions of overweight and obesity. Diabetes Res Clin Pract 107:424–432. https://doi.org/10.1016/j.diabres.2014.09.059

Article  PubMed  Google Scholar 

Atre S, Deshmukh S, Kulkarni M (2020) Prevalence of type 2 diabetes mellitus (T2DM) in India: A systematic review (1994–2018). Diabetes Metab Syndr 14:897–906. https://doi.org/10.1016/j.dsx.2020.05.040

Article  PubMed  Google Scholar 

Sun H, Saeedi P, Karuranga S et al (2022) IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract 183:109119. https://doi.org/10.1016/j.diabres.2021.109119

Article  PubMed  Google Scholar 

Dagenais GR, Gerstein HC, Zhang X et al (2016) Variations in diabetes prevalence in Low-, Middle-, and High-Income countries: results from the prospective urban and rural epidemiological study. Diabetes Care 39:780–787. https://doi.org/10.2337/dc15-2338

Article  CAS  PubMed  Google Scholar 

Al-Kuraishy HM, Al-Gareeb AI, Saad HM et al (2023) The potential effect of Metformin on fibroblast growth factor 21 in type 2 diabetes mellitus (T2DM). Inflammopharmacology 31:1751–1760. https://doi.org/10.3390/nu15071713

Article  CAS  PubMed  Google Scholar 

Ding C, Bao Y, Bai B et al (2022) An update on the economic burden of type 2 diabetes mellitus in China. Expert Rev Pharmacoecon Outcomes Res 22:617–625. https://doi.org/10.1080/14737167.2022.2020106

Article  PubMed  Google Scholar 

Zheng Y, Ley SH, Hu FB (2018) Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol 14:88–98

Article  PubMed  Google Scholar 

Kolb H, Martin S (2017) Environmental/lifestyle factors in the pathogenesis and prevention of type 2 diabetes. BMC Med 15:131. https://doi.org/10.1186/s12916-017-0901-x

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kriska AM, Saremi A, Hanson RL et al (2003) Physical activity, obesity, and the incidence of type 2 diabetes in a high-risk population. Am J Epidemiol 158:669–675. https://doi.org/10.1093/aje/kwg191

Article  PubMed  Google Scholar 

Hou X, Xing B, Zhang G et al (2023) Serum Irisin is associated with bone mineral density in postmenopausal T2DM patients complicated with osteoporosis and in mice with diabetic osteoporosis. Curr Protein Pept Sci 24:355–363. https://doi.org/10.2174/1389203724666230228140808

Article  CAS  PubMed  Google Scholar 

Wu J, Fang Y, Tan X et al (2023) Detecting type 2 diabetes mellitus cognitive impairment using whole-brain functional connectivity. Sci Rep 13:3940

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nauck M, Holst J, Willms B et al (1997) Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes. Exp Clin Endocrinol Diabetes 105:187–195. https://doi.org/10.1055/s-0029-1211750

Article  CAS  PubMed  Google Scholar 

Nauck M, Vardarli I, Deacon C et al (2011) Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia 54:10–18. https://doi.org/10.1007/s00125-010-1896-4

Article  CAS  PubMed  Google Scholar 

Yu B, Lin F, Wang M et al (2022) Efficacy and safety of dulaglutide compared with the first-line hypoglycemic drugs in Asian patients with type 2 diabetes: a systematic review and meta-analysis. Sci Rep 12:18281. https://doi.org/10.1038/s41598-022-22263-4

Article  CAS  PubMed  PubMed Central  Google Scholar 

Thompson AM, Trujillo JM (2015) Dulaglutide: the newest GLP-1 receptor agonist for the management of type 2 diabetes. Ann Pharmacother 49:351–359. https://doi.org/10.1177/1060028014564180

Article  CAS  PubMed  Google Scholar 

Scheen AJ (2017) Dulaglutide for the treatment of type 2 diabetes. Expert Opin Biol Ther 17:485–496. https://doi.org/10.1080/14712598.2017.1296131

Article  CAS  PubMed  Google Scholar 

Gerstein HC, Colhoun HM, Dagenais GR et al (2019) Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394:121–130. https://doi.org/10.1016/s0140-6736(19)31149-3

Article  CAS  PubMed  Google Scholar 

Yang G, Wei J, Liu P et al (2021) Role of the gut microbiota in type 2 diabetes and related diseases. Metabolism 117:154712. https://doi.org/10.1016/j.metabol.2021.154712

Article  CAS  PubMed  Google Scholar 

Zhou Z, Sun B, Yu D et al (2022) Gut microbiota: an important player in type 2 diabetes mellitus. Front Cell Infect Microbiol 12:834485. https://doi.org/10.3389/fcimb.2022.834485

Article  CAS  PubMed  PubMed Central  Google Scholar 

Crommen S, Simon MC (2017) Microbial regulation of glucose metabolism and insulin resistance. Genes (Basel) 9:10. https://doi.org/10.3390/genes9010010

Article  CAS  PubMed  Google Scholar 

Sun Z, Sun X, Li J et al (2020) Using probiotics for type 2 diabetes mellitus intervention: advances, questions, and potential. Crit Rev Food Sci Nutr 60:670–683. https://doi.org/10.1080/10408398.2018.1547268

Article  PubMed  Google Scholar 

Canfora EE, van der Beek CM, Hermes GDA et al (2017) Supplementation of diet with Galacto-oligosaccharides increases bifidobacteria, but not insulin sensitivity, in obese prediabetic individuals. Gastroenterology 153:87–97e83. https://doi.org/10.1053/j.gastro.2017.03.051

Article  CAS  PubMed  Google Scholar 

Wang Y, Dilidaxi D, Wu Y et al (2020) Composite probiotics alleviate type 2 diabetes by regulating intestinal microbiota and inducing GLP-1 secretion in Db/db mice. Biomed Pharmacother 125:109914. https://doi.org/10.1016/j.biopha.2020.109914

Article  CAS  PubMed  Google Scholar 

Tsai CY, Lu HC, Chou YH et al (2021) Gut microbial signatures for glycemic responses of GLP-1 receptor agonists in type 2 diabetic patients: A pilot study. Front Endocrinol (Lausanne) 12:814770. https://doi.org/10.3389/fendo.2021.814770

Article  PubMed  Google Scholar 

Schulz KF, Altman DG, Moher D (2010) CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 340:c332. https://doi.org/10.1136/bmj.c332

Article  PubMed  PubMed Central  Google Scholar 

Faul F, Erdfelder E, Lang AG et al (2007) G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 39:175–191. https://doi.org/10.3758/bf03193146

Article  PubMed  Google Scholar 

Koutnikova H, Genser B, Monteiro-Sepulveda M et al (2019) Impact of bacterial probiotics on obesity, diabetes and non-alcoholic fatty liver disease related variables: a systematic review and meta-analysis of randomised controlled trials. BMJ Open 9:e017995. https://doi.org/10.1136/bmjopen-2017-017995

Article  PubMed  PubMed Central  Google Scholar 

Kuritzky L, Umpierrez G, Ekoé JM et al (2014) Safety and efficacy of dulaglutide, a once weekly GLP-1 receptor agonist, for the management of type 2 diabetes. Postgrad Med 126:60–71. https://doi.org/10.3810/pgm.2014.10.2821

Article  PubMed  Google Scholar 

Deng M, Qu F, Chen L et al (2020) SCFAs alleviated steatosis and inflammation in mice with NASH induced by MCD. J Endocrinol 245:425–437. https://doi.org/10.1530/joe-20-0018

Article  CAS  PubMed